RTP Mobile Logo
What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Gastroesophageal and Colorectal Cancers (Symposium Video Proceedings)
Released June 2024

Featuring perspectives from Ms Deanna A Griffie, Ms Caroline Kuhlman, Dr Manish A Shah and Dr John Strickler. Published June 7, 2024. (Symposium Video Proceedings)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gastroesophageal and colorectal cancers.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with gastroesophageal and colorectal cancers.

    LEARNING OBJECTIVES

    • Appraise clinical trial findings supporting the use of neoadjuvant and/or adjuvant anti-PD-1/PD-L1 antibody therapy for patients with resectable gastric, gastroesophageal junction (GEJ) and esophageal cancer, and discern the clinical applicability of various treatment strategies.
    • Understand how HER2 status, PD-L1 combined positive score, microsatellite instability/mismatch repair status, claudin 18.2 positivity, clinical factors and patient preferences affect the selection of first-line therapy for metastatic gastric, GEJ and esophageal cancer.
    • Describe the published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies in the management of gastric, GEJ and esophageal cancer, and recognize how these strategies should be integrated into current treatment algorithms.
    • Evaluate the biological rationale for the investigation of claudin 18.2 as a therapeutic target in gastric/GEJ cancer, and assess available data with novel strategies directed at this emerging biomarker.
    • Optimize the use of adjuvant chemotherapy for patients with localized colorectal cancer (CRC), considering various clinical and biological factors, such as age, performance status and stage, and the potential relevance of molecular residual disease.
    • Develop an understanding of newly validated biomarkers of response (eg, HER2, microsatellite instability/mismatch repair deficiency, KRAS G12C) found in metastatic CRC (mCRC), and consider the implications for molecular testing and clinical care.
    • Counsel patients with microsatellite instability-high/mismatch repair-deficient mCRC regarding the risks, benefits and optimal use of available immunotherapeutic agents and regimens.
    • Appreciate published and recently presented research data documenting the efficacy of KRAS G12C inhibition for patients with relapsed/refractory mCRC and a KRAS G12C mutation, and consider the potential role of this therapeutic strategy.
    • Understand available research guiding the selection and sequencing of later-line therapeutic options for patients with multiregimen-relapsed mCRC, considering the implications of recently presented Phase III data sets and new FDA approvals.
    • Recall available data with novel HER2-targeted agents and strategies for patients with HER2-overexpressing gastric/GEJ and colorectal cancer, and identify candidates who may be appropriate for these approaches.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CREDIT DESIGNATION STATEMENT
    Video Program: This educational activity for 2.25 contact hours is provided by RTP during the period of June 2024 to June 2025.

    This activity is awarded 2.25 ANCC pharmacotherapeutic contact hours.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2024/GICRC/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    PRIVACY POLICY 
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. 

    FOR SUCCESSFUL COMPLETION
    Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2024/GI/Video/NCPD.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Deanna A Griffie, MSN, AGNP-C
    Nurse Practitioner
    GI Medical Oncology
    Duke Cancer Institute
    Durham, North Carolina

    No relevant conflicts of interest to disclose.

    Caroline Kuhlman, MSN, APRN-BC
    Nurse Practitioner
    Tucker Gosnell Center for Gastrointestinal Cancers
    Massachusetts General Hospital
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Manish A Shah, MD
    Chief, Solid Tumor Oncology Service
    Director, Gastrointestinal Oncology Program
    Co-Director, Center for Advanced Digestive Care
    Bartlett Family Professor of Gastrointestinal Oncology
    Weill Cornell Medicine/
    NewYork-Presbyterian Hospital
    New York, New York

    Contracted Research: Bristol Myers Squibb, Merck, Oncolys BioPharma.

    John Strickler, MD
    Associate Professor
    Associate Director, Clinical Research – GI
    Duke University
    Durham, North Carolina

    Advisory Committees: AbbVie Inc, Agenus Inc, Astellas,AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Natera Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Xilio Therapeutics; Contracted Research: AbbVie Inc, Amgen Inc, A*STAR D3, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Curegenix, Daiichi Sankyo Inc, Erasca, Genentech, a member of the Roche Group, GSK, Leap Therapeutics Inc, Lilly, Novartis, Pfizer Inc, Revolution Medicines; Data and Safety Monitoring Boards/Committees: AbbVie Inc, BeiGene Ltd, GSK, Pfizer Inc; Stock Options — Private Company: Triumvira Immunologics.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

    RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, and Taiho Oncology Inc.

    Release date: June 2024
    Expiration date: June 2025

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):